Neuroendocrine Carcinomas: Patient Paths and Outcomes in Latin America

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study retrospectively collects data from medical records of adults diagnosed with extrapulmonary NEC, LCNEC, or SCLC in Brazil, Mexico, Argentina, and Peru. It describes demographics, diagnostic methods, tumor features, treatments (including surgery, chemotherapy, radiotherapy), and disease progression. Data are gathered using an electronic data capture system, with care aligned to standard clinical practice. The goal is to illuminate real-world treatment patterns and outcomes across the region.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ≥18 years old
* Diagnosed between August 2014 and August 2024 with one of the following:
* Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
* Large-cell neuroendocrine carcinoma (LCNEC) or mixed
* Small Cell Lung Cancer (SCLC) or mixed
* Adequate and accessible medical records for data collection
* Tumor block collected from 2014 onwards

Exclusion Criteria:

* Patients with active, concurrent malignancies at the time of NEC diagnosis, except for non-invasive cancers like basal cell carcinoma or squamous cell carcinoma of the skin, or in situ cervical cancer.
* Patients or their legal representatives unwilling or unable to provide informed consent (if needed per ethics committee).

Where it's running

• Hospital Británico de Buenos Aires
  Buenos Aires, Buenos Aires, Argentina Recruiting
• Hospital de Gastroenterología Carlos Bonorino Udaondo
  Buenos Aires, Buenos Aires, Argentina Recruiting
• Instituto Alexander Fleming
  Buenos Aires, Buenos Aires, Argentina Recruiting
• Oncosalud AUNA
  Lima, Lima Province, Peru Recruiting
• Hospital Evangélico de Cachoeiro de Itapemirim - Centro de Pesquisas Clínicas em Oncologia (CPCO)
  Cachoeiro de Itapemirim, Espírito Santo, Brazil Active not recruiting
• Clínica Prognóstica - Centro de Pesquisa Clínica Onconeo
  Campo Grande, Mato Grosso do Sul, Brazil Active not recruiting

Study contacts

• Principal investigator: Rachel Simões Pimenta Riechelmann — Latin American Cooperative Oncology Group
• Study coordinator: Project Manager
• Email: lacog1324@lacog.group
• Phone: +55 51 3384 5334

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CTX-471 for NCAM-positive metastatic neuroendocrine tumors

  A phase 2 trial is testing CTX-471 in adults with NCAM (CD56) positive metastatic neuroendocrine tumors that have progressed after standard therapy.

  Recruiting at 2 sites Phase 2 Compass Therapeutics · St Louis, Missouri and 1 other locations · NCT07684170

• IDE849 for DLL3-expressing tumors including small-cell lung cancer

  This trial tests IDE849, alone and with durvalumab or IDE161, to see if it is safe and can shrink DLL3-positive tumors in people with small-cell lung cancer or other DLL3-expressing cancers.

  Recruiting at 13 sites Phase 1/2 IDEAYA Biosciences · Denver, Colorado and 12 other locations · NCT07174583

• Testing ADCT-701 for treating neuroendocrine tumors and carcinomas

  This study is testing a new drug called ADCT-701 to see if it can safely help adults with neuroendocrine tumors and certain types of cancer.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06041516

• Phase I testing of 225Ac-ETN029 for advanced DLL3-positive tumors

  This trial will test 225Ac-ETN029, with 111In-ETN029 used for imaging, to see if the treatment is safe, tolerable, and shows early anti-tumor activity in adults with advanced DLL3-positive neuroendocrine cancers.

  Recruiting at 8 sites Phase 1 Novartis · Iowa City, Iowa and 7 other locations · NCT07006727

• Radiation plus tarlatamab for DLL3-expressing tumors

  This trial will test whether giving tarlatamab together with standard palliative or consolidative radiation is safe for adults with DLL3-expressing or DLL3-prevalent tumors such as melanoma, medullary thyroid cancer, sinonasal undifferentiated carcinoma, esthesioneuroblastoma, and bladder cancer.

  Recruiting at 3 sites Phase 1/2 University of Arizona · Gilbert, Arizona and 2 other locations · NCT06814496

• Combining Durvalumab with Etoposide and Platinum for Lung Cancer Treatment

  This study is testing if combining a new immune therapy with chemotherapy can help people with advanced lung cancer feel better and live longer.

  Recruiting at 2 sites Phase 2 Centre Leon Berard · Aix-en-Provence and 30 other locations · NCT06393816

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.